Table 2.
Cumulative risks of cancer among patients with syncope by follow-up time, treating death as competing risk.
| Type of cancer | 0–6 months | >6–12 months | 1–20 years |
|---|---|---|---|
| All | 1.2 (1.2–1.3) | 0.7 (0.7-0.7) | 17.9 (17.3–18.3) |
| Intracranial tumours | |||
| Meninges | 0.1 (0.0–0.1) | <0.1d | 0.2 (0.1–0.2) |
| Brain | 0.1 (0.1–0.1) | <0.1d | 0.4 (0.3–0.5) |
| Supradiaphragmatic tumours | |||
| Pharynxa | <0.1d | <0.1d | 0.2 (0.2–0.3) |
| Lung | 0.2 (0.2–0.2) | 0.1 (0.1–0.1) | 1.8 (1.7–2.0) |
| Tongue | <0.1d | <0.1d | 0.1 (0.0–0.1) |
| Oral cavity | <0.1d | <0.1d | 0.1 (0.1–0.2) |
| Breast | 0.1 (0.1–0.1) | 0.1 (0.1–0.1) | 1.5 (1.4–1.7) |
| Infradiaphragmatic tumours | |||
| Liver | <0.1d | <0.1d | 0.3 (0.2–0.4) |
| Stomach | <0.1d | <0.1d | 0.2 (0.2–0.3) |
| Kidney | <0.1d | <0.1d | 0.2 (0.2–0.3) |
| Colorectalb | 0.2 (0.1–0.8) | 0.1 (0.1–0.1) | 1.9 (1.7–2.0) |
| Oesophagus | <0.1d | <0.1d | 0.2 (0.2–0.3) |
| Prostate | 0.1 (0.1–0.1) | 0.1 (0.1–0.1) | 1.8 (1.7–2.0) |
| Pancreas | <0.1d | <0.1d | 0.4 (0.3–0.4) |
| Ovary | <0.1d | <0.1d | 0.2 (0.1–0.2) |
| Urinary bladder | 0.1 (0.0–0.1) | <0.1d | 0.9 (0.8–1.0) |
| Haematology malignancies | |||
| Non-Hodgkin lymphoma incl. multiple myeloma | 0.1 (0.0–0.1) | <0.1d | 0.6 (0.5–0.7) |
| Leukaemiac | <0.1d | <0.1d | 0.3 (0.2–0.3) |
Data are percentages with 95% confidence intervals
aPharyngeal cancers include cancers in the nasal part of the pharynx, pharyngeal tonsil, the pharyngeal cavity, and other parts of the pharynx (unspecified, Waldeyer’s ring, and overlapping lesions of the lip, oral cavity, and pharynx)
bColorectal cancer includes cancers of the rectum, caecum, anus, appendix, ascending colon hepatic flexure, transverse colon, splenic flexure, descending colon, sigmoid colon, and colon unspecified
cLeukaemia includes: monocytic leukaemia, acute myeloid leukaemia (acute myeloid leukaemia with multilineage dysplasia and myeloid leukaemia, unspecified), and other leukaemias of specified cell type. Lymphoid leukaemia: acute leukaemias, chronic lymphocytic leukaemia of B-cell type, prolymphocytic leukaemia of B-cell type, hairy-cell leukaemia, adult T-cell lymphoma/leukaemia, prolymphocytic leukaemia of T-cell type, other lymphoid leukaemia, mature B-cell leukaemia Burkitt-type, and lymphoid leukaemia, unspecified
dCumulative risk below 0.1% due to low number of outcomes